The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical

Phase III Eribulin Trial Boosts OS in Liposarcoma Patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Data from a phase III trial evaluating eribulin in liposarcoma demonstrated a significant improvement in overall survival.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

In Brief

Ohio State to be awarded funding to optimize sarcoma treatment

The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has been approved for research funding by the Patient-Centered Outcomes Research Institute to study whether adding chemotherapy before standard treatment with immunotherapy, radiation, and surgery for certain sarcomas will reduce the risk of the cancer returning.
Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account